Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sinopharm Group Co ( (HK:1099) ) has issued an update.
Sinopharm Group Co. Ltd. announced that all resolutions proposed at its extraordinary general meeting held on 19 December 2025 in Shanghai were duly passed by poll, reflecting strong shareholder support for changes to its board lineup. Shareholders approved the appointments of Jin Bin and Ma Yue as non-executive directors and Yang Binghua as an executive director, as well as Li Ying as a non-executive director, each with authority granted to the board to determine their remuneration and finalize service contracts, signaling a refreshed governance structure that may influence the group’s strategic direction and oversight.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a major Chinese pharmaceutical and healthcare distributor, operating across the People’s Republic of China and listed in Hong Kong. The company focuses on the distribution of medicines, medical devices and healthcare products, and plays a key role in the country’s pharmaceutical supply chain and healthcare services market.
Average Trading Volume: 4,792,532
Technical Sentiment Signal: Buy
Current Market Cap: HK$61.23B
See more data about 1099 stock on TipRanks’ Stock Analysis page.